Preparation of PCL Electrospun Fibers Loaded with Cisplatin and Their Potential Application for the Treatment of Prostate Cancer.
Journal
Emergency medicine international
ISSN: 2090-2840
Titre abrégé: Emerg Med Int
Pays: Egypt
ID NLM: 101567070
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
06
2022
accepted:
20
06
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
26
7
2022
Statut:
epublish
Résumé
Prostate cancer is a global fatal type of cancer. It is a type of cancer that affect men. Signs and symptoms of the disease include blood in the urine, pain when one micturates, and difficulties in penis erection. Cisplatin chemotherapy is a principal treatment normally given to the prostate cancer patients. Nonetheless, on its own, cisplatin loses efficacy once administered due to liver pass effects and other biochemical attacks. In this paper, we looked at preparation of PCL nanoparticles loaded with cisplatin and their potential for the treatment of prostate cancer. PCL nanoparticles protect cisplatin from biochemical attack, thus increasing drug efficacy. Incorporation of P-glycoprotein inhibitors in PCL nanoparticles (NPs) loaded with cisplatin could improve prostate cancer treatment even more.
Identifiants
pubmed: 35875248
doi: 10.1155/2022/6449607
pmc: PMC9307411
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
6449607Informations de copyright
Copyright © 2022 Hilla Mills et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Oncogene. 2000 Jun 29;19(28):3138-45
pubmed: 10918568
Semin Radiat Oncol. 2013 Jul;23(3):222-34
pubmed: 23763889
Chem Commun (Camb). 2012 May 25;48(42):5151-3
pubmed: 22514015
Expert Opin Ther Targets. 2015;19(10):1307-17
pubmed: 26004625
J Cancer Sci Ther. 2019;11(4):
pubmed: 32148661
Int J Pharm. 2010 Jan 4;383(1-2):236-43
pubmed: 19781605
Cancer Res. 2003 Dec 15;63(24):8977-83
pubmed: 14695216
Am J Prev Med. 2013 Sep;45(3):318-26
pubmed: 23953359
J Surg Oncol. 2014 Jun;109(8):830-5
pubmed: 24610744
Bioorg Med Chem Lett. 2010 Jun 1;20(11):3413-5
pubmed: 20434912
Ann Intern Med. 1979 Sep;91(3):502-3
pubmed: 475203
Prostate Cancer Prostatic Dis. 2006;9(4):374-8
pubmed: 16926855
Biomaterials. 2012 Feb;33(5):1596-606
pubmed: 22079777
Int J Clin Exp Med. 2015 Oct 15;8(10):19670-81
pubmed: 26770631
Biomaterials. 2008 May;29(13):1989-2006
pubmed: 18281090
Int J Nanomedicine. 2014 Jun 28;9:3175-82
pubmed: 25061294
Chem Soc Rev. 2009 Dec;38(12):3484-504
pubmed: 20449064
Biotechnol Adv. 2010 May-Jun;28(3):325-47
pubmed: 20100560
Colloids Surf B Biointerfaces. 2014 Mar 1;115:15-21
pubmed: 24316584
Nanoscale Res Lett. 2017 Dec;12(1):318
pubmed: 28460490
Angew Chem Int Ed Engl. 2007;46(30):5670-703
pubmed: 17585397
Pharmaceutics. 2018 Dec 24;11(1):
pubmed: 30586852
J Nanosci Nanotechnol. 2012 May;12(5):4019-27
pubmed: 22852342
Nature. 1969 Apr 26;222(5191):385-6
pubmed: 5782119
Mol Med Rep. 2015 Jun;11(6):4561-6
pubmed: 25625867
Colloids Surf B Biointerfaces. 2011 May 1;84(1):97-102
pubmed: 21227661
J Clin Oncol. 2003 Jun 1;21(11):2199-210
pubmed: 12775747
Nanoscale Res Lett. 2014 May 23;9(1):257
pubmed: 25114629